**Supplemental Tables:**

|  |  |  |  |
| --- | --- | --- | --- |
| ART | Yes | No | P-Value |
| Current PI use | 92±22 | 100±22 | 0.01 |
| Current NRTI use | 94±21 | 103±25 | 0.06 |
| Current NNRTI use | 92±22 | 95±22 | 0.45 |
| Current TDF use | 94±21 | 102±25 | 0.04 |
| Current abacavir use | 93±24 | 97±22 |  0.49 |
| Current raltegravir use | 95±22 | 96±23 | 0.73 |
| Current efavirenz use | 103±21 | 94±23 | 0.01 |
|  |  |  |  |

Supplemental Table 1: eGFR based on class and type of Antiretroviral Therapy

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |
|  | Total severity of coronary plaque score | Total coronary segments with plaque | Coronary segments with calcified plaque | Coronary segments with non-calcified plaque | Agatston score |
|  | (R2=0.04, P=0.58) |  (R2=0.11, P=0.06) | (R2=0.08, P=0.16) | (R2=0.20, P=0.004) | (R2=0.08, P=0.16) |
|  |  β |  P |  β |  P |  β |  P0.490.090.07 |  β |  P |  β |  P |
| Total Framingham point score | 0.11 | 0.18 | 0.13 | 0.01 | -0.01 | 0.10 | 0.0005 | 2.18 | 0.19 |
| eGFR | -0.005 | 0.80 | -0.009 | 0.50 | -0.006 | 0.007 | 0.26 | -0.33 | 0.38 |
| BMI | -0.03 | 0.74 | -0.001 | 0.98 | 0.03 | -0.05 | 0.08 | 2.47 | 0.18 |

Supplemental Table 2: Correlation between eGFR and Agatston score and coronary plaque after adjusting for traditional cardiovascular risk factors in HIV negative controls.